CervoMed Inc. Common Stock
CRVOCervoMed Inc. (CRVO) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative and inflammatory diseases. The company leverages advanced scientific research to create novel treatment options aimed at improving patient outcomes in areas with significant unmet medical needs.
Company News
CervoMed Inc. announced that its drug candidate neflamapimod has been selected for inclusion in the UK's EXPERTS-ALS platform, a government-funded clinical trial designed to rapidly test potential ALS treatments. The trial will initially evaluate neflamapimod in approximately 35 ALS patients over 18-24 weeks, with potential expansion to 80 patien...
CervoMed presented Phase 2b trial results showing neflamapimod significantly slows clinical progression in dementia with Lewy bodies, with most prominent improvements in patients without AD co-pathology. The company plans to initiate Phase 3 trials in 2026.
CervoMed shared Phase 2b trial data showing neflamapimod treatment reduced neuroinflammation biomarkers in Dementia with Lewy Bodies patients, with promising results indicating potential disease progression slowing.
CervoMed will present new data on neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting results from their Phase 2b RewinD-LB trial.
EmergingGrowth.com announced the schedule for its 87th conference featuring presentations from multiple small-cap companies across various sectors on October 22-23, 2025, providing insights into emerging growth opportunities.
